文献速递临床试验与 GCP基础与转化研究

地舒单抗阻断RANKL治疗侵蚀性手骨关节炎:一项随机安慰剂对照2a期试验

RANKL blockade for erosive hand osteoarthritis: a randomized placebo-controlled phase 2a trial.
PubMed 文献 · Nat Med · 2024-02-15

这项单中心、安慰剂对照、双盲、随机2a期临床试验评估地舒单抗对侵蚀性手骨关节炎结构改变的作用。患者随机接受地舒单抗60 mg每3个月一次(n=51)或安慰剂(n=49)治疗48周。主要终点第24周GUSS变化组间估计差异为8.9(95%CI 1.0至16.9;P=0.024),第48周确认差异为14.3(95%CI 4.6至24.0;P=0.003),安慰剂组新发侵蚀关节更多(OR 0.24,95%CI 0.08至0.72;P=0.009)。

要点

  • 地舒单抗60 mg每3个月一次治疗48周,第24周GUSS组间差异8.9(95%CI 1.0至16.9;P=0.024)。
  • 第48周GUSS组间差异14.3(95%CI 4.6至24.0;P=0.003),安慰剂组新发侵蚀关节更多(OR 0.24,95%CI 0.08至0.72;P=0.009)。
  • 安慰剂组不良事件125例(44例患者,90%),地舒单抗组97例(41例患者,80%)。

核心结论

  • 地舒单抗在侵蚀性手骨关节炎中具有结构改善作用,可诱导重塑并预防新发侵蚀关节。

研究设计与样本

  • 单中心、安慰剂对照、双盲、随机2a期临床试验。
  • 患者随机接受48周地舒单抗60 mg每3个月一次(n=51,41例女性)或安慰剂(n=49,37例女性)治疗。

主要发现

  • 主要终点第24周GUSS变化组间估计差异为8.9(95%CI 1.0至16.9;P=0.024)。
  • 第48周基线校正GUSS在地舒单抗组和安慰剂组分别为163.5(均值标准误2.9)和149.2(均值标准误3.9),组间估计差异为14.3(95%CI 4.6至24.0;P=0.003)。
  • 第48周患者水平新发侵蚀关节安慰剂组多于地舒单抗组(OR 0.24,95%CI 0.08至0.72;P=0.009)。
  • 不良事件安慰剂组125例(44例患者,90%),地舒单抗组97例(41例患者,80%)。

关键数值与推荐

  • 主要放射学终点为第24周GUSS总评分变化,正变化对应重塑,负变化对应侵蚀进展。
  • 次要终点为第48周GUSS变化及第48周按解剖分期评分系统的新发侵蚀关节数。
  • 基线目标关节平均GUSS(标准差)在地舒单抗组为155.9(69.3),安慰剂组为158.7(46.8)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Erosive hand osteoarthritis (OA) is a prevalent and disabling disease with limited treatment options. Here we present the results of a monocentric, placebo-controlled, double-blind, randomized phase 2a clinical trial with denosumab, a receptor activator of nuclear factor-κB ligand inhibitor, evaluating the effects on structure modification in erosive hand OA. Patients were randomized to 48 weeks treatment with denosumab 60 mg every 3 months (n = 51, 41 females) or placebo (n = 49, 37 females). The primary (radiographic) endpoint was the change in the total Ghent University Scoring System (GUSS) at week 24, where positive changes correspond to remodeling and negative changes to erosive progression. Secondary endpoints were the change in the GUSS at week 48 and the number of new erosive joints at week 48 by the anatomical phase scoring system. Baseline mean GUSS (standard deviation) of target joints was 155.9 (69.3) in the denosumab group and 158.7 (46.8) in the placebo group. The primary endpoint was met with an estimated difference between groups of 8.9 (95% confidence interval (CI) 1.0 to 16.9; P = 0.024) at week 24. This effect was confirmed at week 48 (baseline adjusted GUSS (standard error of the mean) denosumab and placebo were 163.5 (2.9) and 149.2 (3.9), respectively; with an estimated difference between groups of 14.3 (95% CI 4.6 to 24.0; P = 0.003)). At patient level, more new erosive joints were developed in the placebo group compared with denosumab at week 48 (odds ratio 0.24 (95% CI 0.08 to 0.72); P = 0.009). More adverse events occurred in the placebo group (125 events in 44 patients (90%)) compared with the denosumab group (97 events in 41 patients (80%)). These results demonstrate that denosumab has structure modifying effects in erosive hand OA by inducing remodeling and preventing new erosive joints. EU Clinical Trials Register identifier 2015-003223-53 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Wittoek R, Verbruggen G, Vanhaverbeke T, et al. RANKL blockade for erosive hand osteoarthritis: a randomized placebo-controlled phase 2a trial. Nat Med. 2024. PMID: 38361122. doi:10.1038/s41591-024-02822-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。